Logo image of VIV.CA

AVIVAGEN INC (VIV.CA) Stock Fundamental Analysis

TSX-V:VIV - TSX Venture Exchange - CA05382F2026 - Common Stock - Currency: CAD

0.005  0 (0%)

Fundamental Rating

2

VIV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of VIV have multiple concerns. VIV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VIV had negative earnings in the past year.
In the past year VIV has reported a negative cash flow from operations.
In the past 5 years VIV always reported negative net income.
In the past 5 years VIV always reported negative operating cash flow.
VIV.CA Yearly Net Income VS EBIT VS OCF VS FCFVIV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -1702.53%, VIV is not doing good in the industry: 95.12% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -1702.53%
ROE N/A
ROIC N/A
ROA(3y)-282.16%
ROA(5y)-251.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VIV.CA Yearly ROA, ROE, ROICVIV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K

1.3 Margins

VIV has a better Gross Margin (42.70%) than 65.85% of its industry peers.
VIV's Gross Margin has declined in the last couple of years.
VIV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.51%
GM growth 5Y-8.78%
VIV.CA Yearly Profit, Operating, Gross MarginsVIV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K -15K -20K -25K

More info and screens

0

2. Health

2.1 Basic Checks

VIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VIV has more shares outstanding
VIV has a worse debt/assets ratio than last year.
VIV.CA Yearly Shares OutstandingVIV.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
VIV.CA Yearly Total Debt VS Total AssetsVIV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -311.25, we must say that VIV is in the distress zone and has some risk of bankruptcy.
VIV has a worse Altman-Z score (-311.25) than 95.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -311.25
ROIC/WACCN/A
WACC4.24%
VIV.CA Yearly LT Debt VS Equity VS FCFVIV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 2M -2M 4M -4M

2.3 Liquidity

VIV has a Current Ratio of 0.03. This is a bad value and indicates that VIV is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.03, VIV is doing worse than 97.56% of the companies in the same industry.
VIV has a Quick Ratio of 0.03. This is a bad value and indicates that VIV is not financially healthy enough and could expect problems in meeting its short term obligations.
VIV has a Quick ratio of 0.02. This is amonst the worse of the industry: VIV underperforms 97.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.02
VIV.CA Yearly Current Assets VS Current LiabilitesVIV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.00% over the past year.
VIV shows a decrease in Revenue. In the last year, the revenue decreased by -7.92%.
VIV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.72% yearly.
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.09%
Revenue 1Y (TTM)-7.92%
Revenue growth 3Y-1.32%
Revenue growth 5Y29.72%
Sales Q2Q%-16.62%

3.2 Future

Based on estimates for the next years, VIV will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
VIV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 396.99% yearly.
EPS Next Y31.33%
EPS Next 2Y37.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year243.05%
Revenue Next 2Y396.99%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIV.CA Yearly Revenue VS EstimatesVIV.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
VIV.CA Yearly EPS VS EstimatesVIV.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 -0.05 -0.1 -0.15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIV. In the last year negative earnings were reported.
Also next year VIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIV.CA Price Earnings VS Forward Price EarningsVIV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIV.CA Per share dataVIV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08 -0.1

4.3 Compensation for Growth

VIV's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.32%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VIV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVIVAGEN INC

TSX-V:VIV (3/5/2024, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)01-04 2022-01-04
Inst Owners0.1%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap388.47K
Analysts84.44
Price Target1.02 (20300%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.54
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.01
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1702.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.7%
FCFM N/A
ROA(3y)-282.16%
ROA(5y)-251.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.51%
GM growth 5Y-8.78%
F-Score2
Asset Turnover2.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.03
Quick Ratio 0.02
Altman-Z -311.25
F-Score2
WACC4.24%
ROIC/WACCN/A
Cap/Depr(3y)13.91%
Cap/Depr(5y)1026.59%
Cap/Sales(3y)1.48%
Cap/Sales(5y)4.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.09%
EPS Next Y31.33%
EPS Next 2Y37.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.92%
Revenue growth 3Y-1.32%
Revenue growth 5Y29.72%
Sales Q2Q%-16.62%
Revenue Next Year243.05%
Revenue Next 2Y396.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.8%
OCF growth 3YN/A
OCF growth 5YN/A